The introduction of imatinib has substantially changed the approaches to the therapy of chronic myeloid leukemia. However, this drug can cause hepatic failure and death in rare cases. This report describes a clinical case of acute, toxic imatinib-induced hepatitis in a 56-year-old woman with chronic myeloid leukemia and concomitant sulfa allergy and rheumatoid arthritis. The patient developed acute imatinib-induced hepatitis after three months of treatment with imatinib and three days after increasing the imatinib dosage from 400 mg per day to 600 mg per day, resolving within three months after imatinib discontinuation and prednisolone administration. This confirms the necessity of great caution during imatinib therapy and the monitoring of liver tests. Approximately 25 reports about clinical cases of imatinib-induced hepatitis have been published up to the present.

No abstract

No abstract

The fight against infectious agents is a topical issue of the day, and treatment of the infectious pathology in rheumatological patients of is often presents a difficult task. The main problems faced by rheumatologists include presence of new pathogens, the role of opportunistic microflora and increased influence of the resistant microorganisms, the issue of the effectiveness and interaction of antibacterial drugs with antirheumatic drugs. All the above listed necessitates the search and development of new schemes and methods of antibiotic therapy in rheumatology. The main diseases associated with bacterial infection include reactive arthritis, Lyme arthritis against the background of Lyme borreliosis, bacterial (septic) arthritis, and others. The authors performed the analysis of literature sources and international recommendations regarding the possibilities of using antibacterial drugs for reactive arthritis, Lyme arthritis and bacterial (septic) arthritis. The current schemes of rational antibacterial therapy are presented. The timely treatment of chlamydial urogenital infection in patients with reactive arthritis plays an important role. The effectiveness of the treatment of the early stages of Lyme arthritis, that is, at the stage of erythema migrans, was noted, which may be the primary prevention of joint damage. Combinations and timing of antibiotic therapy for bacterial (septic) arthritis are highlighted. It should be remembered that a bacterial infection can be a trigger for the development of rheumatological pathology, therefore, the timely use of adequate antibiotic therapy, in some cases, can be considered the primary prevention of certain diseases. Therefore, the development of effective schemes for rational antibiotic therapy and monitoring of infectious agents are urgent problems. Rheumatologists should be aware of new recommendations for the management of patients with infectious diseases and timely prescribe the most effective regimens and therapy programs.

The pandemic of coronavirus 2 (severe acute respiratory syndrome (SARSCoV-2) has significantly changed lives around the world. Musculoskeletal symptoms can develop with SARS-CoV-2 as with other respiratory infections. Viral infections can be cause of arthritis, but the spectrum of symptoms can be quite wide, from arthralgia to chronic arthritis. Coronaviruses can be usually cause of arthralgia and myalgia rather than clinical arthritis. However, a syndrome of dysregulation and systemic overactivation of the immune system, described as a cytokine storm or hyperinflammatory syndrome, can developduring the course of COVID-19. As a result, coagulation and inflammation can significantly affect the progression of the disease and possibly lead to damageof the musculoskeletal system.The aim of the publication is to raise the awareness of rheumatologists and general practitioners, we offer a clinical case of the development of a musculoskeletal system lesion in a patient with COVID-19 and the successful treatment of this condition in this patient.Patients and methods. The article presents a clinical case of patient Z., who was diagnosed with joint lesions on the background of coronavirus infection.The patient was hospitalized in the rheumatology department of the Communal Non-profit Enterprise of the Kharkov Regional Council «Kharkiv RegionalHospital».Results and discussion. The patient underwent a full range of clinical and diagnostic studies and was prescribed systemic therapy with corticosteroids,supportive, as well as antibiotic therapy. The decrease of joint damage symptoms was noted during therapy. Subsequent observation was indicatedan improvement in the patient’s condition after the end of treatment in hospital.Conclusions. Our own experience in the treatment and management of the patient with a lesion of the musculoskeletal system against the background of coronavirus infection presens in the article. The data on clinical cases that were accompanied by joint damage against the background of COVID-19 or occurred some time after a viral infection were presented. Important practical clinical issues related to the diagnosis and management of patients withatypical manifestations of the disease are considered.